Molecular Imaging for Idiopathic Pulmonary Fibrosis
This study is looking for 10 participants with Idiopathic Pulmonary Fibrosis (IPF), a lung disease that causes scarring. Researchers want to see if special imaging scans, called PET/CT, using two substances called [F-18]FDG and [F-18]DPA-714, can help them understand lung inflammation and scarring in IPF. You would have two separate imaging sessions. The goal is to compare the results from these scans with your lung function tests to better understand IPF and potentially improve future treatments. To join, you must be between 40 and 85 years old and have an IPF diagnosis within the last five years.
- Study design
- This is an interventional study with a planned enrollment of 10 participants. It is not specified if it is randomized or blinded.
- What's involved
- Participants will undergo PET/CT scans with [F-18]FDG and [F-18]DPA-714 in two separate imaging sessions. Lung function tests will be measured from screening up to 48 hours after the second imaging visit.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary endpoint measures are taken from screening up to 48 hours after the second imaging visit.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Molecular Imaging Probes to Inform Heterogeneity in Idiopathic Pulmonary Fibrosis
At a glance
Conditions
NCT04362644
Where you'd take part
This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
The University of Alabama at Birmingham
Birmingham, Alabamastudy coordinator listed
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Correlate quantitative PET measures of lung inflammation with [F-18]FDG and [F-18]DPA-714 to pulmonary function tests.screening to 48 hours post 2nd imaging visit.